Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $5.3 million.

  • Intellia Therapeutics' Gains from Investment Securities fell 3.77% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 3.77%. This contributed to the annual value of $5.4 million for FY2024, which is 0.85% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Gains from Investment Securities of $5.3 million as of Q3 2025, which was down 3.10% from $5.4 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Gains from Investment Securities peaked at $109.7 million during Q4 2024, and registered a low of $235,858 during Q1 2024.
  • Its 3-year average for Gains from Investment Securities is $14.6 million, with a median of $5.5 million in 2024.
  • Data for Intellia Therapeutics' Gains from Investment Securities shows a peak YoY increase of 8,960.36% (in 2024) and a maximum YoY decrease of 96.01% (in 2024) over the last 5 years.
  • Intellia Therapeutics' Gains from Investment Securities (Quarterly) stood at $6.2 million in 2021, then surged by 307.31% to $25.3 million in 2022, then slumped by 95.20% to $1.2 million in 2023, then skyrocketed by 8,960.36% to $109.7 million in 2024, then declined by 3.77% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $5.4 million for Q2 2025, and $5.9 million during Q1 2025.